Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:05 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 976 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Endothelial Clear all

Conditions: Spinal Cord Injuries, Cardiovascular Diseases, Endothelial Dysfunction
Interventions: Brachial intra-arterial infusion of vasoactive and antioxidant drugs (acetylcholine, nitroprusside, ascorbic acid), venous occlusion plethysmography, Acetylcholine, Sodium Nitroprusside, Ascorbic acid, venous phlebotomy; Procedure · Drug
Lead sponsor: Craig Hospital; Other
Eligibility: 18 Years to 89 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Englewood, Colorado

Conditions: Macular Degeneration
Interventions: Pazopanib; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 50 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 16
States / cities: Tucson, Arizona • Beverly Hills, California • Pasadena, California + 13 more

Conditions: Obstructive Sleep Apnea, Hypoxemia
Interventions: Continuous Positive Airway Pressure (CPAP); Device
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 21 Years and older
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetic Macular Edema
Interventions: Ozurdex, Bevacizumab; Drug
Lead sponsor: Raj K. Maturi, MD; Individual
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Heart Failure, Decompensated Heart Failure
Interventions: Not listed
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2022
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Peritoneal Cancer
Interventions: Bevacizumab, Oxaliplatin, Paclitaxel; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Healthy Subjects
Interventions: Watermelon Rind, Watermelon Flesh, Watermelon Seeds, Placebo; Dietary Supplement
Lead sponsor: Clinical Nutrition Research Center, Illinois Institute of Technology; Industry
Eligibility: 20 Years to 45 Years
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Advanced Cancer
Interventions: EPC2407 (crinobulin); Drug
Lead sponsor: EpiCept Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 3
States / cities: Scottsdale, Arizona • Beverly Hills, California • San Diego, California

Conditions: HIV Infections
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2007
U.S. locations: 9
States / cities: Los Angeles, California • San Diego, California • Honolulu, Hawaii + 4 more

Conditions: Treatment Induced Hypertension
Interventions: Minoxidil, Hydralazine; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Smoking
Interventions: E-cigarette/tobacco Smoking Exposure; Device
Lead sponsor: NYU Langone Health; Other
Eligibility: 21 Years to 40 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Cognitive Impairment, Hypertension, Aging
Interventions: candesartan, lisinopril, hydrochlorothiazide, nifedipine, long acting, metoprolol, long-acting; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 60 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 2
States / cities: Los Angeles, California • Boston, Massachusetts

Conditions: Obesity, Hypertension
Interventions: Angiotensin-(1-7), Saline; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Type 2 Diabetes
Interventions: Extra Virgin Olive Oil, Refined Olive Oil; Other
Lead sponsor: Griffin Hospital; Other
Eligibility: 25 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Derby, Connecticut

Conditions: Preeclampsia
Interventions: Not listed
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Borderline High LDL-cholesterol
Interventions: Ubiquinol, Ubiquinone, Placebo; Dietary Supplement · Other
Lead sponsor: SF Research Institute, Inc.; Network
Eligibility: 35 Years to 65 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Diastolic Heart Failure, Hypertensive Heart Disease, Heart Failure With Preserved Ejection Fraction, Hypertension, Oxidative Stress
Interventions: grape seed extract (MegaNatural BP, Polyphenolics, Inc.); Drug
Lead sponsor: University of Michigan; Other
Eligibility: 50 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Obstructive Sleep Apnea
Interventions: Not listed
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: HIV Infection, Cardiovascular Disease, Inflammation, HIV Infections
Interventions: Maraviroc, placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: San Francisco, California

Conditions: ADPKD
Interventions: Spironolactone, Sugar pill; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 20 Years to 55 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Healthy
Interventions: Miconazole, L-NMMA, Bradykinin; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Not listed
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Endotheliopathies
Interventions: Konan SP4000, NIDEK CEM-350; Device
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Coronary Arteriosclerosis, Non ST Segment Elevation Acute Coronary Syndrome
Interventions: OrbusNeich Combo stent™, Everolimus Eluting Stent (EES); Device
Lead sponsor: OrbusNeich; Industry
Eligibility: 20 Years and older
Enrollment: 572 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 17
States / cities: Washington D.C., District of Columbia • Lake Worth, Florida • Miami, Florida + 14 more

Conditions: Cystic Fibrosis
Interventions: Acute Antioxidant, Chronic Antioxidant, Placebo; Dietary Supplement · Other
Lead sponsor: Augusta University; Other
Eligibility: 7 Years and older
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2027
U.S. locations: 1
States / cities: Augusta, Georgia

Search by objective public record fields.

Role of Endothelial Function in SCI CVD Risk

To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD

Mechanisms of Endothelial Cell Dysfunction in Sleep Apnea

Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Alone Versus Ozurdex Given Every 3 Months for Treatment of Persistent Diabetic Macular Edema

Monocyte Phenotypic Changes in Heart Failure

Oxaliplatin and Paclitaxel Plus Bevacizumab in Advanced Peritoneal Carcinomatosis

Bioavailability and Pharmacokinetic Parameters of Watermelon (Rind, Flesh and Seeds) Polyphenols

A Safety Study of EPC2407, A Anti-Cancer Drug With Vascular Disrupting Activity: In Patients With Advanced Cancer

Blood Vessel Function in HIV-Infected Patients Taking Anti-HIV Drugs

Pilot Study of the Treatment of Vascular Endothelial Growth Factor(VEGF)Signaling Pathway Inhibitor-Induced Hypertension

Effect of Electronic Cigarettes on Platelets, Endothelium and Inflammation

The Antihypertensives and Vascular, Endothelial and Cognitive Function Trial

Cardiovascular Effects of Angiotensin-(1-7) in Obesity Hypertension

Post-prandial Effects of Extra Virgin Olive Oil on Endothelial Function in Adults at Risk for Type 2 Diabetes

Racial Differences: Nitric Oxide(NO) and Endothelin-1(ET-1) in Preeclampsia (PreE)

Effects of Ubiquinol and Ubiquinone on Vascular Function in Healthy Adults With Borderline High LDL-Cholesterol

Physiological Effects of Grape Seed Extract in Diastolic Heart Failure

Study to Assess the Changes in Blood Clotting Factors and Blood Vessel Wall Function in Obstructive Sleep Apnea

Effect of Maraviroc on Endothelial Function in HIV-Infected Patients

Mineralocorticoid Antagonism and Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Effects of Miconazole on Blood Flow

Specular Microscopy Study

HARMONEE - Japan-USA Harmonized Assessment by Randomized, Multi-Center Study of OrbusNEich's Combo StEnt

Mechanisms for Vascular Dysfunction and Exercise Tolerance in CF